Swiss drug major Novartis (NOVN: VX) this morning reported that fourth-quarter net income rose 2% to $2.06 billion, missing analyst forecasts of $2.4 billion. Net income attributable to shareholders rose 2% to $2.03 billion from a restated $1.99 billion.
Novartis said group sales in the three months increased 2% to $15.08 billion (+4% at constant currency), boosted by growth in recently-launched products and strong sales in countries such as China and Russia. Analysts polled by Dow Jones Newswires had forecast sales of $15.09 in the quarter.
For the full year, group net sales rose 2% (+4% cc) to $57.9 billion. Operating income of $10.9 billion fell 3% (+5% cc). Core operating income of $14.5 billion declined 2% (+3% cc).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze